One key reason every investor should know about CRISPR Therapeutics (CRSP) is that it is the world’s first biotechnology company to successfully commercialize a CRISPR-based gene-editing therapy. This milestone not only validates its scientific capabilities but also lays a solid foundation for future growth.
For a long time, the pharmaceutical industry faced repeated setbacks in DNA repair research, with few achievements translating into actual drugs. However, at the end of 2023, Casgevy, co-developed by CRISPR Therapeutics and its partner Vertex (VRTX), received approval from the U.S. FDA for the treatment of sickle cell disease, making it the world’s first CRISPR-based gene-editing drug. This breakthrough not only reflects the maturity of the company’s technology but also marks the official arrival of a new era in gene therapy.
Although the market size for sickle cell disease itself is limited, the significance of the FDA’s first approval extends far beyond a single disease area. Currently, the company is advancing six new drug clinical trials based on the same technology platform, including two oncology drugs and two cardiovascular disease therapies—areas with immense unmet medical needs and market potential. According to Straits Research, the global CRISPR gene-editing drug market is expected to achieve an average annual growth rate of nearly 25% by 2033. As an industry pioneer, CRISPR Therapeutics is poised to benefit directly from this trend.
Of course, competition in the gene-editing field is intensifying. Besides CRISPR Therapeutics, Bluebird Bio (BLUE) has also gained approval for a gene therapy targeting the same indication, while companies like Beam Therapeutics (BEAM) and Intellia Therapeutics (NTLA) are actively expanding their pipelines. Nevertheless, CRISPR Therapeutics maintains a leading position in the R&D competition, thanks to its first-mover advantage and continuous innovation capabilities. Analysts predict that with the gradual commercialization of Casgevy, the company’s revenue could see multi-fold growth next year.
In the second quarter of 2025, the company’s stock price rose by 43%, partly due to its inclusion in the Russell Index, which attracted increased attention from institutional investors. Prominent investment firms like ARK Investment Management have also continued to increase their holdings in the stock recently, reflecting market confidence in its long-term prospects. Currently, analysts generally assign a “Moderate Buy” rating, with an average target price of approximately $71.6, indicating market recognition of its potential while also reminding investors to be mindful of short-term volatility and valuation risks.
In summary, the core investment highlights of CRISPR Therapeutics lie in its successful commercialization of a groundbreaking drug using its revolutionary technology platform and its demonstrated potential to expand into additional therapeutic areas. Despite facing competition and profitability challenges, the company’s leading position and growth prospects make it a noteworthy representative enterprise in the gene-editing field.
